Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
CIA-Linked Investor Helped Quantum Systems Expand in US 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
OpenAI Nears Astra AI Model Launch With Safety Focus 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
-- Company presentation scheduled for March 27, 2018 --
SOUTH SAN FRANCISCO, Calif., March 14, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present at Needham & Company’s 17th Annual Healthcare Conference taking place March 27 to 28, 2018 in New York. Achaogen management will present at 2:00 p.m. Eastern Time on Tuesday, March 27th, 2018.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived on the website for 30 days following the conference.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination for the treatment of serious bacterial infections due to ESBL-producing Enterobacteriaceae. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
